{"type":"trials","record":{"id":34987,"source_id":"clinicaltrials-gov","external_id":"NCT07449364","title":"Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient","brief_summary":"Subjects will be provided a written informed consent to participate in the study and then undergo any screening. Subjects who meet all the inclusion criteria and none of the exclusion criteria based on the screening test results will be included into the study. At treatment day, the subjects will be administered 100 million cells of investigational product for 30 minutes for each package using a syringe pump. After 4 weeks (1 month) of Investigational product administration, the subjects will visit the study site to evaluate the safety and efficacy of investigational products. Follow up visits for potential efficacy will also be conducted after 12 weeks (3 months) and 24 weeks (6 months) of Investigational product administration. If necessary, additional examination and treatment may be performed according to the investigator's judgment","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Daewoong Group Indonesia","enrollment":10,"countries":["Indonesia"],"start_date":"2025-03-24","completion_date":"2025-12-05","last_update_date":"2026-03-04","source_url":"https://clinicaltrials.gov/study/NCT07449364","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:20.087268+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years to 85 Years","comparator":null,"organization":"Daewoong Group Indonesia","interventions":["Daewoong Biologics Indonesia Umbilical Cord-derived Mesenchymal Stem Cell (DBI UC-MSC)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety evaluation — 1, 3, and 6 months","Safety evaluation — 2 hours, 1 month, 3 months, and 6 months","Efficacy evaluation (Frailty state) — 1, 3, and 6 months","Efficacy evaluation (Patient quality of life) — 1, 3, and 6 months","Efficacy evaluation (Inflammatory biomarkers) — 1, 3, and 6 months","Efficacy evaluation (Immune system biomarkers) — 1, 3, and 6 months"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Frailty in Older Adults","Daewoong Biologics Indonesia Umbilical Cord-derived Mesenchymal Stem Cell (DBI UC-MSC)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct07449364","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-03-24 to 2025-12-05","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.458Z","intervention":["Daewoong Biologics Indonesia Umbilical Cord-derived Mesenchymal Stem Cell (DBI UC-MSC)"],"participants":10,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety evaluation — 1, 3, and 6 months","Safety evaluation — 2 hours, 1 month, 3 months, and 6 months","Efficacy evaluation (Frailty state) — 1, 3, and 6 months","Efficacy evaluation (Patient quality of life) — 1, 3, and 6 months","Efficacy evaluation (Inflammatory biomarkers) — 1, 3, and 6 months","Efficacy evaluation (Immune system biomarkers) — 1, 3, and 6 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Source terminology contains: frailty.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/34987","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}